Clinical trials: Gene, p53
Recurrent Bladder Cancer, Stage I Bladder Cancer
Gene Therapy in Treating Patients With Advanced Bladder Cancer
Phase I trial to study the effectiveness of gene therapy in treating patients with advanced bladder cancer. Inserting the p53 gene into a person's bladder cancer cells may improve the body's ability to fight cancer
- Conditions
- Recurrent Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
- Trial name
- NCT00003167
- Testing
- Ad5CMV-p53 gene
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Inserting the gene for p53 into a person's tumor may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003257
- Testing
- Ad5CMV-p53 gene
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Aventis Pharmaceuticals
Anti-p53 TCR-Gene
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Background: The p53 gene normally suppresses tumor growth, but when it is mutated, or damaged, tumors can grow unchecked. In cancers where the p53 gene has mutated, an increased level of p53(overexpression of p53) can be measured…
- Trial name
- NCT00393029
- Testing
- anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
This clinical trial is an open label Phase II study of the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
- Trial name
- NCT02340117
- Testing
- SGT-53, nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- SynerGene Therapeutics, Inc.
Colorectal Cancer
Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00280761
- Testing
- capecitabine, 5-fluorouracil, Surgical Resection
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Neoplasms, TP53 Gene Mutation
Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma
The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor tissue samples.
- Conditions
- Endometrial Neoplasms, TP53 Gene Mutation, Chromosomal Instability, Microsatellite Stable Endometrial Carcinoma
- Trial name
- NCT06521684
- Volunteers
- 110 people
- Sponsor
- Peking Union Medical College Hospital
Li-Fraumeni Syndrome, Hereditary Cancer Syndromes
Biomarker Monitoring in TP53 Mutation Carriers
Purpose This study is an 'N-of-one' observational study focusing on individuals with a hereditary predisposition to cancer due to a genetic mutation in the TP53 gene.
- Conditions
- Li-Fraumeni Syndrome, Hereditary Cancer Syndromes, TP53 Gene Germline Mutation Carrier
- Trial name
- NCT02289326
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Scripps Health
Non-muscle Invasive Bladder Cancer
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 combined with gemcitabine for patients who have BCG failure (defined as refractory, relapsing or intolerant), non-muscle invasive bladder…
- Trial name
- NCT01625260
- Testing
- ALT-801, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Altor BioScience
Li-Fraumeni Syndrome, TP53 Gene Mutation
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g.
- Conditions
- Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis
- Trial name
- LiFT_UP (NCT04541654)
- Testing
- Data and Specimen Collection
- Where
- 3 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer
Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma
The primary objectives of this study are to investigate the efficacy and safety of surgery combined with rAd-p53 gene therapy in treatment of advanced Non-small-cell lung carcinoma (NSCLC).
- Trial name
- rAd-p53 (NCT01574729)
- Testing
- Surgery combined with rAd-p53 gene therapy, Surgery
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Neoplasms
p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , with concurrent radiotherapy, or combination with surgery…
- Trial name
- NCT00894153
- Testing
- chemotherapy plus p53, chemotherapy, radiotherapy
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Mouth Cancer
Wild Type p53 Adenovirus for Oral Premalignancies
Primary Objectives: 1. To determine the maximum tolerated dose and transduction efficiency of adenoviral mediated wild type p53 gene transfer in premalignancies of the upper aerodigestive tract. 2.
- Trial name
- NCT00410865
- Testing
- INGN 201
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
HIV-1 Seropositive, Inflammation
Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage
Background: Research has shown that certain proteins in cells may be linked to higher risks of developing inflammations, tumors, and other medical problems.
- Conditions
- HIV-1 Seropositive, Inflammation, Cancer, Cardiomyopathy
- Trial name
- NCT01143519
- Where
- United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
EGFR Gene Amplification, EGFR Gene Mutation
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and osimertinib works in evaluating glucose utilization in patients with EGFR activated glioblastoma.
- Conditions
- EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma
- Trial name
- NCT03732352
- Testing
- Fludeoxyglucose F-18, Osimertinib, Positron Emission Tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
RATIONALE: Inserting the gene for adenovirus p53 into a person's tumor may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have recurrent…
- Trial name
- NCT00004041
- Testing
- Ad5CMV-p53 gene, conventional surgery
- Where
- 8 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Pleural Effusion
Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion
Objective of this study is to investigate of efficacy and safety of recombinant adenoviral human p53 Gene (rAd-p53) in treatment of malignant pleural effusion, compared to cisplatin.
- Trial name
- NCT02429726
- Testing
- rAdp53, Cisplatin, rAdp53 plus cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Paediatric Osteosarcomas
Genetic Characterisation of High-grade Paediatric Osteosarcomas
At present, the only recognised prognostic factor for primary high-grade osteosarcoma is the histological response to preoperative chemotherapy.
- Trial name
- NCT00223184
- Where
- 2 sites in France
- Sponsor
- University Hospital, Strasbourg, France
Ovarian Cancer
Gene Therapy in Treating Patients With Ovarian Cancer
Phase I trial to study the effectiveness of gene therapy in treating patients with ovarian cancer that has not responded to previous treatment.
- Trial name
- NCT00003588
- Testing
- Ad5CMV-p53 gene, laparoscopic surgery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
This is a study of the safety and efficacy of adavosertib in combination with paclitaxel plus carboplatin in the treatment of ovarian, fallopian tube, and primary peritoneal tumors with the P53 mutation.
- Trial name
- NCT01357161
- Testing
- adavosertib, paclitaxel, carboplatin
- Volunteers
- 136 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphadenectomy, Endometrial Cancer
SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in p53-Mutated Endometrial Cancer: A Non-Inferiority Randomized Trial
This study evaluates surgical strategies for treating patients with FIGO 2023 stage I and II high-risk endometrial cancer (EC) exhibiting p53 mutations.
- Conditions
- Lymphadenectomy, Endometrial Cancer, Gene, p53, Sentinel Lymph Node Biopsy (SLNB)
- Trial name
- SENTIMETREP53 (NCT06900582)
- Testing
- Sentinel Lymph Node Mapping, Comprehensive pelvic and para-aortic lymphadenectomy
- Volunteers
- 374 people
- Sponsor
- University Hospital, Strasbourg, France